Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Kristen Kluska - Cantor Fitzgerald Malcolm Kuno - JPMorgan Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Jeff Hung - Morgan Stanley Joshua Fleishman - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Full Year 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago.
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
Amicus Therapeutics: Cheap Heading Into 2025
Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. Galafold dominates its market segment, and a licensing deal with Teva de-risks future growth, positioning it for a continued revenue increase.
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
